What is Chardan Capital's Forecast for OCUL FY2025 Earnings?

Key Points

• Chardan Capital predicts that Ocular Therapeutix will report FY2025 earnings of ($1.45) per share, with a price target of $21.00 and a "Buy" rating on the stock.
• In Q2, Ocular Therapeutix reported a loss of ($0.39) EPS, underperforming expectations, while quarterly revenues totaled $13.46 million.
• Several analysts have upgraded their price targets for Ocular Therapeutix, with the lowest target now at $19.00 and an average consensus rating of "Moderate Buy."

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - Research analysts at Chardan Capital issued their FY2025 earnings per share estimates for shares of Ocular Therapeutix in a research report issued on Wednesday, October 15th. Chardan Capital analyst D. Gataulin expects that the biopharmaceutical company will earn ($1.45) per share for the year. Chardan Capital has a "Buy" rating and a $21.00 price objective on the stock. The consensus estimate for Ocular Therapeutix's current full-year earnings is ($0.98) per share. Chardan Capital also issued estimates for Ocular Therapeutix's FY2026 earnings at ($0.99) EPS.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.04). Ocular Therapeutix had a negative return on equity of 71.92% and a negative net margin of 382.51%.The firm had revenue of $13.46 million for the quarter, compared to analyst estimates of $13.12 million. During the same period in the prior year, the company posted ($0.26) EPS. The firm's quarterly revenue was down 17.7% compared to the same quarter last year.

OCUL has been the topic of a number of other research reports. Needham & Company LLC increased their price target on Ocular Therapeutix from $15.00 to $20.00 and gave the company a "buy" rating in a research note on Wednesday, October 1st. HC Wainwright increased their price target on Ocular Therapeutix from $15.00 to $19.00 and gave the company a "buy" rating in a research note on Wednesday, October 8th. Zacks Research raised Ocular Therapeutix from a "strong sell" rating to a "hold" rating in a research note on Thursday, October 2nd. Piper Sandler increased their price target on Ocular Therapeutix from $21.00 to $31.00 and gave the company an "overweight" rating in a research note on Friday, October 3rd. Finally, Scotiabank cut their price target on Ocular Therapeutix from $22.00 to $20.00 and set a "sector outperform" rating on the stock in a research note on Wednesday, August 6th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $22.63.

Ocular Therapeutix Stock Performance

OCUL stock opened at $11.84 on Monday. The business's fifty day moving average is $12.24 and its 200-day moving average is $10.05. The company has a quick ratio of 10.02, a current ratio of 10.10 and a debt-to-equity ratio of 0.23. The company has a market cap of $2.06 billion, a P/E ratio of -9.25 and a beta of 1.45. Ocular Therapeutix has a twelve month low of $5.78 and a twelve month high of $13.85.

Institutional Trading of Ocular Therapeutix

A number of large investors have recently made changes to their positions in the company. Union Bancaire Privee UBP SA bought a new stake in shares of Ocular Therapeutix in the 3rd quarter valued at $298,000. Osaic Holdings Inc. increased its holdings in Ocular Therapeutix by 19,194.3% during the 2nd quarter. Osaic Holdings Inc. now owns 67,530 shares of the biopharmaceutical company's stock worth $627,000 after purchasing an additional 67,180 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Ocular Therapeutix by 96.6% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 61,995 shares of the biopharmaceutical company's stock worth $575,000 after purchasing an additional 30,460 shares in the last quarter. Marex Group plc bought a new position in Ocular Therapeutix during the 2nd quarter worth about $115,000. Finally, Hudson Bay Capital Management LP bought a new position in Ocular Therapeutix during the 2nd quarter worth about $502,000. Institutional investors own 59.21% of the company's stock.

Insider Activity

In related news, insider Jeffrey S. Heier sold 10,502 shares of the company's stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $11.04, for a total value of $115,942.08. Following the completion of the sale, the insider owned 249,409 shares in the company, valued at $2,753,475.36. This represents a 4.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Pravin Dugel sold 21,494 shares of the company's stock in a transaction on Monday, August 25th. The shares were sold at an average price of $12.04, for a total transaction of $258,787.76. Following the completion of the sale, the insider owned 3,227,244 shares of the company's stock, valued at approximately $38,856,017.76. This represents a 0.66% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 61,806 shares of company stock worth $727,648 in the last 90 days. Corporate insiders own 2.30% of the company's stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.